U.S. Gene Therapy Markets

Table of Contents

• 1. Executive Summary
  • 1. Executive Summary
    • 1. Executive Summary
• 2. Introduction to Gene Therapies
  • 1. Introduction
    • 1. Market Overviews
    • 2. The History of Gene Therapy
    • 3. Recent Developments in Gene Therapy Research
    • 4. Toxicities and Fatalities with Gene Therapies
    • 5. Gendicine -- the First Approved Gene Therapy in the World
    • 6. The Human Genome Project
  • 2. Basic Genetic Terminologies and Definitions
    • 1. Objectives of Gene Therapy
    • 2. Basic Genetic Terminology
    • 3. Gene Therapy Vectors
    • 4. Gene Regulation
    • 5. Gene Therapy Targets
• 3. Gene Therapy Delivery Market Segments
  • 1. Introduction and Overview
    • 1. Gene Delivery Systems
    • 2. Features of Ideal Gene Vectors
    • 3. Regulation of Transgene Expression Systems
    • 4. Gene Delivery Variables
  • 2. Vectors in Gene Therapy
    • 1. Viral Vectors
    • 2. Retroviral Vectors
    • 3. Lentiviral Vectors
    • 4. Adenoviral Vectors
    • 5. Adeno-associated Viral (AAV) Vectors
    • 6. Vaccinia Vectors
    • 7. Herpes Simplex Virus (HSV) Vectors
    • 8. Other Viral Vectors
  • 3. Non-Viral Delivery Technologies in Gene Therapy
    • 1. Non-viral Delivery Technologies in Gene Therapy
    • 2. Calcium Phosphate and DEAE Dextran
    • 3. Liposomes
    • 4. Electroporation-mediated Gene Delivery Technology
    • 5. Naked Plasmid DNA Injection
    • 6. Compacted DNA Technology (DNA nanoparticles)
    • 7. Microinjection
    • 8. Ballistic DNA Injection
  • 4. Novel Non-viral Gene Therapy Technologies
    • 1. Overview
    • 2. Synthetic Minichromosomes/Artificial Chromosomes
    • 3. Gene Switching & Activation Technology
    • 4. Multiple and Novel Vector Technologies
    • 5. Transposon Vector Gene Therapy
    • 6. Gene Targeting
    • 7. Genetically-modified Bacteria
    • 8. Spliceosome-mediated Gene Therapy
    • 9. Glycomics
• 4. U.S. Gene Therapies Markets
  • 1. Market Overview
    • 1. Introduction
    • 2. Market Drivers
      • a. Outdated Legacy Systems
      • b. Payment Mechanism is Highly Dependant on Administrative Systems
      • c. Cost is Decreasing
      • d. Efficiencies in Cost-containment in Business Processes
    • 3. Market Restraints
      • a. Low Budgets for IT Modernisation/Spending Priorities
      • b. Resistance to Change
      • c. Infrastructure/Integration Issues
      • d. Country Specific Solutions
      • e. Barriers to Entry are Very High for New Entrants
      • f. Patient-centric HIS Markets in Europe
    • 4. Market Engineering Measurements
  • 2. Market Forecasts and Competitive Analysis
    • 1. Research Methodology and Assumptions
    • 2. Revenue Forecasts
    • 3. Competitive Landscape
    • 4. Competitive Factors
  • 3 Challenges and Strategic Recommendations
    • 1. Industry Challenges
    • 2. Strategic Recommendations
  • 4. Awards
    • 1. Product Innovation Award
    • 2. Technology Innovation Award
    • 3. Entrepreneurial Company Award
    • 4. Business Development Strategy Leadership Award
• 5. Gene Therapy Application Market Segments
  • 1. Introduction
    • 1. Gene Therapy Application Market Segments
  • 2. Monogenic Disease Therapy
    • 1. Overview
    • 2. Revenue Forecasts
  • 3. Cancer Gene Therapy
    • 1. Overview
    • 2. Revenue Forecasts
  • 4. Cardiovascular Gene Therapy
    • 1. Overview
    • 2. Revenue Forecasts
  • 5. Other Gene Therapies
    • 1. Overview
    • 2. Revenue Forecasts
• 6. Appendix
  • 1. Decision Support Databases
    • 1. Physicians
    • 2. Specialized Medical Practioner
    • 3. Total Population
    • 4. Pharma R&D Expenditures
    • 5. Percent Pharma R&D Expenditure

List Of Figures

Chapter 2

• Gene Therapy Market: Applications of Gene Therapy (U.S.), 2004

Chapter 3

• Gene Therapy Market: Companies Developing Retroviral and Lentiviral Vectors (U.S.), 2004
• Gene Therapy Market: Companies Developing Adenoviral Vectors (U.S.), 2004
• Gene Therapy Market: Companies Developing Adeno-Associated Viral Vectors (U.S.), 2004
• Gene Therapy Market: Companies Developing Other Viral Vectors (U.S.), 2004
• Gene Therapy Market: Companies Developing Liposomal (Lipid-Based) Vectors (U.S.), 2004
• Gene Therapy Market: Companies Developing Episomal (Plasmid DNA-Based) Vectors (U.S.), 2004
• Gene Therapy Market: Companies Developing Novel and / or Multi Technologies (U.S.), 2004

Chapter 4

• Total Gene Therapy Market: Market Drivers Ranked in Order of Impact (U.S.), 2005-2011
• Total Gene Therapy Market: Market Restraints Ranked in Order of Impact (U.S.), 2005-2011
• Total Gene Therapy Market: Seven-Step Market Engineering Forecast Methodology (U.S.), 2004
• Total Gene Therapy Market: Revenue Forecasts (U.S.), 2001-2011
• Total Gene Therapy Market: Segment-Wise Revenue Forecasts (U.S.), 2001-2011
• Total Gene Therapy Market: Competitive Structure (U.S.), 2004
• Total Gene Therapy Market: Ranking and Impact of the Top Ten Industry Challenges (U.S.) 2005-2011

Chapter 5

• Gene Therapy Market: Monogenic Disease Segment Phase 2 Trials (U.S.), 2004
• Gene Therapy Market: Monogenic Disease Targets under Investigation (U.S.), 2004
• Gene Therapy Market: Monogenic Diseases Revenue Forecasts (U.S.), 2001-2011
• Gene Therapy Market: Cancer Segment Phase 3 Trials (U.S.), 2004
• Gene Therapy Market: Cancer Segment Phase 2 Trials (U.S.), 2004
• Gene Therapy Market: Cancer Targets under Investigation (U.S.), 2004
• Gene Therapy Market: Cancer Segment Revenue Forecasts (U.S.), 2001-2011
• Gene Therapy Market: Cardiovascular Disorders Segment Phase 2 Trials (U.S.), 2004
• Gene Therapy Market: Cardiovascular Disorders Targets under Investigation (U.S.), 2004
• Gene Therapy Market: Cardiovascular Disorders Revenue Forecasts (U.S.), 2001-2011
• Gene Therapy Market: Other Disease Targets under Investigation (U.S.), 2004
• Gene Therapy Market: Others Segment Phase 2 Trials (U.S.), 2004
• Gene Therapy Market: Others Segment Revenue Forecasts (U.S.), 2001-2011